Teleflex Incorporated
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a TFX research report →
Range $158 – $170
Price Chart
About the company
Teleflex Incorporated is a global medical technology company dedicated to designing, developing, manufacturing, and distributing single-use medical devices. These products are crucial for diagnostic and therapeutic procedures, particularly within critical care and surgical environments worldwide. Its comprehensive product portfolio includes: Vascular Access Solutions: Featuring the "Arrow" brand, these include catheters, advanced catheter navigation and tip positioning systems, and intraosseous access systems.
- CEO
- Jason Weidman
- IPO
- 1980
- Employees
- 15,500
- HQ
- Wayne, PA, US
Get TickerSpark's AI analysis on TFX
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $6.41B
- P/E
- 19.96
- Fwd P/E
- 21.05
- PEG
- -0.08
- P/S
- 2.92
- P/B
- 1.97
- EV/EBITDA
- 24.45
- Div Yield
- 0.82%
- Gross Margin
- 58.32%
- Op Margin
- 9.85%
- Net Margin
- 13.61%
- ROE
- 9.74%
- ROIC
- 3.15%
Latest fiscal year · YoY change
- Revenue
- $1.99B-34.6%
- Gross Profit
- $1.12B-34.2%
- Op Income
- $255.80M
- Net Income
- $-905,640,000-1399.8%
- EPS
- $-20.30-1462.4%
- OCF Growth
- -46.4%
- FCF Growth
- -51.8%
- 52W High
- $166.75
- 52W Low
- $100.18
- 50D MA
- $135.62
- 200D MA
- $128.65
- Beta
- 0.83
- RSI (14)
- 75
- Avg Volume
- 789.99K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Teleflex posted solid Q3 growth and margin expansion, raised full-year EPS guidance, and said its 2027 setup should improve as the transformation and divestitures progress.· November 5, 2026
- Q3 revenue was $567.8 million, up 0.2% year over year on a GAAP basis and up 3.0% on a pro forma adjusted constant currency basis.
- Adjusted EPS was $2.63, up 39.2% year over year, while adjusted operating margin reached 25% and adjusted gross margin was 66.8%.
- Vascular revenue rose 4.6% and Surgical revenue rose 5.1%; Interventional was up 0.2% and showed improvement versus Q2 despite ongoing integration disruption.
- Management raised full-year 2026 adjusted EPS guidance to $7.50 to $7.75 from $6.90 to $7.20, while keeping pro forma adjusted constant currency revenue growth guidance at 3.5% to 4.5%.
- The company repurchased about $350 million of stock since July 1 and reiterated confidence that the Acute Care and Interventional Urology divestiture will close, though timing could slip into 2027.
Teleflex reported third-quarter 2026 continuing-operations revenue of $567.8 million, up 0.2% year over year on a GAAP basis and up 3.0% on a pro forma adjusted constant currency basis. Adjusted EPS was $2.63, up 39.2% year over year. Adjusted gross margin was 66.8%, up 450 basis points year over year, and adjusted operating margin was 25%, up 300 basis points year over year. For 2026, the company kept pro forma adjusted constant currency revenue growth guidance at 3.5% to 4.5%, raised adjusted EPS guidance to $7.50 to $7.75, and now expects adjusted operating margin of approximately 20%. Management also said Q4 includes a planned step-up in R&D spending tied to BIOMAG-III, and that 2027 should show a clearer financial profile once divestitures close and capital deployment continues.
Jason Weidman framed 2026 as a transition year and emphasized that Teleflex is undergoing a broad transformation toward a more focused, global business-unit structure. He said the company is making real progress on integration, divestitures, and capital allocation, and he repeatedly pointed to 2027 as a year that should benefit from higher margins, lower interest expense, a lower share count, and a step-up in EPS. His tone was constructive and confident, but he also stressed that the work ahead is still substantial and that the company is building its growth profile carefully.
John Deren said adjusted gross margin reached 66.8%, helped by a 290 basis point benefit from a refund related to 2026 IEEPA tariff payments, while adjusted operating margin was 25% and adjusted net interest expense fell to $18.9 million from $30 million a year ago. He noted cash, cash equivalents and restricted cash equivalents of $444.3 million, net leverage of about 1.4x versus 2.8x at Q2, and approximately $350 million of share repurchases since July 1, including about 2.7 million shares at an average price of $128.96. He also reiterated the $1 billion buyback authorization, the $800 million debt reduction goal, full-year 2026 net interest expense of about $85 million, and an adjusted tax rate expectation of about 11.5%.
Analysts focused on Interventional’s return to positive growth, asking when the integration disruptions would fade and when the business could return to company-average or market growth. Management said customer ordering-platform conversion is about 90% complete, 87% of the indirect business has moved under Teleflex control, and sales-force openings are down 63% from peak, but they would not give a specific completion date; they described the improvement as continuous and expected modest sequential improvement in Interventional. Questions also centered on the Acute Care and Interventional Urology divestiture timing, with management saying the deal could slip into 2027 but that they remain confident it will close and are not changing their conviction around the 12-month post-close margin framework. On EZPLAZ, management said the U.S. market opportunity is now viewed as at least $200 million, the product should be immaterial in 2026 and a contributor in 2027, and initial supply will largely go to government and military customers while pricing and margin impacts are still being worked out.
The call showed broad-based execution improvement, with Vascular and Surgical both growing well and Interventional moving in the right direction after a difficult integration period. Management also sounded encouraged by two new growth assets, Freesolve and EZPLAZ, and believes the company is laying groundwork for a stronger 2027 with lower debt, a smaller share count and better margins.
Interventional is still being disrupted by the BIOTRONIK integration, and management would not commit to a precise timing for when it returns to steady market growth. The Acute Care and Interventional Urology divestiture could slip into 2027, and Q4 margins are expected to face pressure from higher R&D spending and other investments. EZPLAZ also remains a long-term build, with no final price set and most early capacity expected to be absorbed by government and military demand.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 99.6%
- Shares Outstanding
- 39.66M
- Float Shares
- 39.50M
of shares held by institutions
390 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Congressional trading
Senate and House stock disclosures for TFX, newest first.
| Member | Type | Traded | |
|---|---|---|---|
| Lisa C. McClainHouse · MI09 | Sell | Jul 22, 25 | Filing → |
| Lisa C. McClainHouse · MI09 | Buy | Jul 16, 25 | Filing → |
| Robert P. BresnahanHouse · PA08 | Sell | Feb 25, 25 | Filing → |
| Ro KhannaHouse · CA17 | Sell | Oct 2, 23 | Filing → |
| Ro KhannaHouse · CA17 | Buy | Aug 29, 23 | Filing → |
| Daniel GoldmanHouse · NY10 | Sell | Jul 12, 23 | Filing → |
| Daniel GoldmanHouse · NY10 | Buy | Apr 10, 23 | Filing → |
| Susie LeeHouse · NV03 | Sell | Nov 30, 22 | Filing → |
| Ro KhannaHouse · CA17 | Sell | Aug 1, 22 | Filing → |
| Ro KhannaHouse · CA17 | Sell | May 5, 22 | Filing → |
| Ro KhannaHouse · CA17 | Buy | May 10, 22 | Filing → |
| Ro KhannaHouse · CA17 | Buy | Feb 14, 22 | Filing → |
| Ro KhannaHouse · CA17 | Sell | Jan 11, 22 | Filing → |
| Susie LeeHouse · NV03 | Buy | Jun 28, 21 | Filing → |
Source: public STOCK Act disclosures. Filed weeks after the trade — a lagging signal, not a real-time one.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Blackrock, Inc. | 5.21M | ▼ 218.97K |
| Vanguard Group Inc | 4.76M | ▼ 37.80K |
| Janus Henderson Group Ltd. | 4.35M | ▲ 4.35M |
| Jupiter Topco LLC | 4.34M | ▲ 4.34M |
| T. Rowe Price Investment Management, Inc. | 2.58M | ▼ 615.46K |
| Vanguard Portfolio Management LLC | 2.32M | ▼ 92.50K |
| Vanguard Capital Management LLC | 1.90M | ▼ 91.03K |
| Sessa Capital Im, L.P. | 1.53M | 0 |
| State Street Corp | 1.44M | ▼ 41.27K |
| Fuller & Thaler Asset Management, Inc. | 1.20M | ▼ 117.62K |
| Dimensional Fund Advisors LP | 1.18M | ▲ 26.48K |
| Invesco Ltd. | 1.11M | ▲ 535.27K |
Held by 432 ETFs
Biggest fund positions in TFX by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Sep 8, 26 | Salmon Sean | other | 4,444 |
| Sep 8, 26 | Salmon Sean | other | 674 |
| Sep 8, 26 | Salmon Sean | other | 0 |
| Jun 8, 26 | RANDLE STUART A | other | 4,663 |
| Jun 8, 26 | RANDLE STUART A | other | 995 |
| Jun 7, 26 | RANDLE STUART A | other | 4,054 |
| Jun 8, 26 | RANDLE STUART A | other | 2,192 |
| Jun 8, 26 | Weidman Jason R. | other | 53,983 |
| Jun 8, 26 | Weidman Jason R. | other | 26,071 |
| Jun 8, 26 | Weidman Jason R. | other | 0 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our TFX coverage
Recent articles, reports, and earnings notes.
No research on TFX yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate TFX report →Teleflex Incorporated (TFX) Presents at Jefferies Global Healthcare Conference 2026 Transcript
seekingalpha.com · Nov 18
Teleflex: The Market Is Pricing The Transition, Not The Company Coming Out Of It
seekingalpha.com · Nov 13
Teleflex to Present at the Jefferies Global Healthcare Conference in London
businesswire.com · Nov 11
Teleflex Q3 Earnings Call Highlights
defenseworld.net · Nov 8
Teleflex Q3 Earnings Call Highlights
marketbeat.com · Nov 8
Teleflex Incorporated (TFX) Q3 2026 Earnings Call Transcript
seekingalpha.com · Nov 5
Teleflex (TFX) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
zacks.com · Nov 5
Teleflex (TFX) Q3 Earnings Surpass Estimates
zacks.com · Nov 5
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.